MONROVIA, Calif.--(BUSINESS WIRE)--Feb. 14, 2006--Xencor, Inc., a biotherapeutics company developing protein and antibody therapeutics, today announced that it has granted Centocor Research and Development, Inc. a non-exclusive license to use Xencor’s ImmunoFilter(TM) technology to evaluate the potential immunogenicity of therapeutic proteins. ImmunoFilter is a predictive tool designed to enable Xencor and its partners to identify risk of future immunogenicity in antibody and other protein therapeutic candidates. Immunogenicity may reduce the therapeutic efficacy of a protein drug and may trigger potentially severe adverse events.
